GeneTex is using its recombinant monoclonal antibody production platform and enhanced validation strategies to create reliable reagents for Mpox research.
The monkeypox virus (MPXV) is the causative agent of the disease known as Mpox. MPXV is an Orthopoxvirus with a double-stranded DNA genome that codes for over 190 nonoverlapping open reading frames (ORFs). Though endemic in certain regions of Africa, since 2017 the incidence of Mpox in other countries has increased with a recent global outbreak that began in May, 2022. Though a vaccine is available, more research focusing on MPXV biology and antiviral drug development is essential.
Recombinant monoclonal antibodies (rAbs) have become invaluable tools for both basic molecular virology and diagnostics. Recombinant technology allows antibodies to be cloned and therefore defined by their amino acid sequence, ensuring consistent identity and performance as well as inexhaustible supply. In addition, they can be easily engineered to meet researcher needs. These unique attributes distinguish rAbs from traditional polyclonal and hybridoma-based monoclonal antibodies, where lot-to-lot variability has precipitated problematic issues such as irreproducible performance and supply unreliability.
GeneTex is mobilizing its recombinant antibody production platform to establish a catalog of unique monoclonal antibody reagents to facilitate Mpox research. In addition to the four MPXV products already available, other antibodies are in development. For more information, please see the products below or contact us.
We gladly support you by keeping you updated on our latest products and the developments around our services.
Direct contact technical support
Find products for your research
